603590 Beijing Konruns Pharmaceutical
- 28.30
- +0.18+0.64%
Beijing Konruns Pharmaceutical News
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
Kangchen Pharmaceutical (603590.SH): Awarded the Eighth Batch of National Manufacturing Individual Champion Enterprises
Gelonghui, May 20, 丨 Kangchen Pharmaceutical (603590.SH) announced that according to the “Guiding Opinions on Accelerating the Cultivation and Development of Quality Manufacturing Enterprises” and “Notice of the General Office of the Ministry of Industry and Information Technology on Carrying Out the 2023 Manufacturing Industry Champion Enterprise Selection, Certification and Evaluation Work”, etc., after Beijing Kangchen Pharmaceutical Co., Ltd., formal review by the Beijing Federation of Industrial Economics and Information Technology, inspection and recommendation by the Beijing Municipal Bureau of Economy and Information Technology, and the Ministry of Industry and Information Technology organized the China Industrial Economics Federation and other third party agencies to verify, verify, and publicize procedures, etc. The company relied on viper blood clotting enzyme (trade name:”
Gelonghui announcement selection | Bull Group: 2023 net profit of 3.87 billion yuan, up 21.37% year on year; CNOOC: net profit of 39.719 billion yuan in the first quarter, up 23.7% year on year
[Performance Data] Kangchen Pharmaceutical (603590.SH): Net profit attributable to parent increased by 48.24% to 150 million yuan in 2023. Kangchen Pharmaceutical (603590.SH) will release the 2023 annual report. In 2023, the company achieved operating income of 920 million yuan, an increase of 6.15% over the same period of the previous year; net profit attributable to owners of the parent company was 150 million yuan, an increase of 48.24% over the same period last year; net profit attributable to owners of the parent company after deducting non-recurring profit and loss was 127 million yuan, an increase of 42.51 million yuan over the same period of the previous year %; basic earnings per share 0.
Kangchen Pharmaceutical (603590.SH): Net profit of 41.6543 million yuan in the first quarter increased 62.28% year-on-year
Gelonghui, April 25, 丨 Kangchen Pharmaceutical (603590.SH) released its report for the first quarter of 2024, achieving operating income of 199 million yuan, an increase of 20.67%; net profit attributable to shareholders of listed companies was 41.6543 million yuan, an increase of 62.28% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 39.6567 million yuan, an increase of 74.63% year on year; basic earnings per share were 0.27 yuan.
Kangchen Pharmaceutical (603590.SH) Performance Report: Net profit of 150 million yuan in 2023 increased 48.24% year on year
Gelonghui, April 8 | Kangchen Pharmaceutical (603590.SH) announced the 2023 Annual Performance Report. During the reporting period, the company achieved total operating revenue of 920 million yuan, an increase of 6.15% over the same period of the previous year; net profit attributable to shareholders of listed companies was 150 million yuan, an increase of 48.24% over the same period of the previous year; during the reporting period, the company's main sales product “Suling” obtained medical insurance renewals and restrictions, and the market access advantage of “Suling” was further expanded. The company seized the opportunity and took a series of measures to improve the availability of drugs and improve the efficacy, safety, and pharmacoeconomics of “Suling” The advantages of this aspect are transferred to the clinic
Kangchen Pharmaceutical (603590.SH): The company “Suling” currently has no export plans
Gelonghui, March 11 | Kangchen Pharmaceutical (603590.SH) said on an interactive platform that the company “Suling” currently has no export plans. If there is specific progress on related matters, the company will disclose relevant information according to regulations, so please pay attention to the company's announcement. “Suling” still has a lot of room for expansion in the domestic market.
5.91% of the company's shares held by the actual controller of Kangchen Pharmaceutical (603590.SH) were judicially frozen
According to Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) issued an announcement. On February 29, 2024, the company learned through an inquiry from China Securities Registration and Settlement Co., Ltd. that due to shareholder lawsuits disclosed by the company on February 26, 2024 and the plaintiff's application for property preservation with the court, the court judicially froze 9.463,500 shares of the company's actual controller Liu Jianhua, accounting for 18.63% of the company's total share capital.
Kangchen Pharmaceutical (603590.SH): KC1036 combined with PD-1 antibody first-line maintenance treatment for locally advanced or metastatic esophageal squamous cell carcinoma obtained a clinical trial notice
Gelonghui December 26丨Kangchen Pharmaceutical (603590.SH) announced that the company has received the “Clinical Trial Notice” of “KC1036 combined with PD-1 antibody first-line maintenance treatment for locally advanced or metastatic esophageal squamous cell carcinoma” approved and issued by the State Drug Administration. KC1036 is a Class 1 innovative chemical drug independently developed by the company, and the company has global intellectual property rights for this product. KC1036 achieves anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL. KC1036 has a strong VEGFR vascular target and inhibits tumor cell growth; by inhibiting AXL,
Kangchen Pharmaceutical (603590.SH): KC1036's Phase III Clinical Study for Advanced Esophageal Squamous Cell Carcinoma Receives CDE Approval
Gelonghui November 28丨Kangchen Pharmaceutical (603590.SH) announced that KC1036 tablets are Class 1.1 innovative drugs independently developed by Beijing Kangchen Pharmaceutical Co., Ltd., based on the results of phase IB/II clinical trials that have already been carried out, the company submitted to the National Drug Administration Drug Evaluation Center (“CDE”) a “random, controlled, open, multi-center phase III clinical study for patients with advanced recurrent or metastatic esophageal cancer squamous disease” plan selected by researchers and obtained approval. The company will launch KC1036 in the near future to treat advanced esophageal squamous cell carcinoma
Kangchen Pharmaceutical (603590.SH): The company's main products sold are “Suling” and “Meegege”
On November 7, some investors asked Kangchen Pharmaceutical (603590.SH) on the investor interactive platform, “Does your company have R&D pharmaceuticals for diseases such as mammary glands, dermatitis, joints, epilepsy, tumors, cancer, genetic mitochondria, etc., as well as health care products such as weight loss drugs and fitness equipment, please give examples.” The company stated that the company focuses on innovative drugs and adheres to clinical value orientation, based on filling in innovative drug development that does not meet clinical needs, giving full play to the company's superior position in the fields of hemostasis, perioperative period, bone metabolism, oncology and immunity, focusing on promoting innovative drug research and development to enhance the sustainable development of enterprises
[BT Financial Report Instantaneous Analysis] Kangchen Pharmaceutical's 2023 Three-Quarter Report: Assets, liabilities, profits, and cash flow grew steadily, and the innovative drug business continued to gain strength
This financial report was announced on 2023-10-27 17:42:35 Kangchen Pharmaceutical (stock code: 603590) is a company focusing on pharmaceutical manufacturing, mainly engaged in R&D and production in the fields of hemostasis, perioperative period, oncology/immunity, and bone metabolism. The company takes innovation as the core, clinical value as the guide, and is committed to becoming an innovative, international and high-quality Chinese pharmaceutical brand enterprise. The company's main products include “Surin” and “Meganite”. First, in terms of assets and liabilities, Kangchen Pharmaceutical's total assets reached 3.777 billion yuan at the end of this reporting period, compared to the end of the previous year
Kangchen Pharmaceutical (603590.SH): KC1036 pediatric medication clinical trial application accepted
Kangchen Pharmaceutical (603590.SH) issued an announcement. Recently, the company received approval and issuance from the State Drug Administration...
Kangchen Pharmaceutical (603590.SH): Golden Herb Phase III clinical trial completed, and all subjects were enrolled
Gelonghui, August 22丨Kangchen Pharmaceutical (603590.SH) announced that recently, Beijing Kangchen Pharmaceutical Co., Ltd. has completed the phase III clinical trial of Jincao tablets, an innovative traditional Chinese medicine drug, to treat chronic pelvic pain as a sequelae of pelvic inflammatory disease. All participants have been enrolled. Golden clover tablets (myostitis) are an effective site preparation extracted from a single traditional Chinese medicine, myoderma sinensis. It is the first innovative Chinese medicine class 1.2 that has been accurately replicated with the indication “chronic pelvic pain as a sequelae of pelvic inflammatory disease”. Currently, no treatment for chronic pelvic pain as a sequelae of pelvic inflammatory disease has been approved in China. According to 2
Kangchen Pharmaceutical (603590.SH) awarded 3.5 million restricted shares at a price of 17.03 yuan/share
Kangchen Pharmaceutical (603590.SH) announced that for the first time stipulated in the company's “2023 Restricted Stock Incentive Plan”...
Kangchen Pharmaceutical (603590.SH): Proposes to launch a restricted stock incentive plan for 4.375 million shares
On July 31, | Kangchen Pharmaceutical (603590.SH) announced the 2023 Restricted Stock Incentive Plan. The number of restricted shares to be granted under this incentive plan is 4.375 million shares, accounting for 2.734% of the company's total share capital of 16,000 million shares at the time of the announcement of this draft incentive plan. Of these, 3.5 million shares were granted for the first time, accounting for 2.188% of the company's total share capital of 16,000.00 million shares at the time of the announcement of this draft incentive plan; 875,000 shares were reserved, accounting for 0.547% of the total share capital of the company at the time the draft incentive plan was announced.
Kangchen Pharmaceutical (603590.SH) appoints Niu Zhanqi as president
According to the Zhitong Finance App, Kangchen Pharmaceutical (603590.SH) announced that the company's board of directors recently received a written resignation report submitted by CEO Liu Jianhua. Liu Jianhua applied to resign as the company's president. The board of directors of the company agreed to appoint Niu Zhanqi as the company's president for a term of office from the date of review and approval by the board of directors until the end of the fourth board of directors.
Kangchen Pharmaceutical (603590.SH): Chairman Wang Xijuan resigns and Liu Jianhua takes over
GLONGHUI July 20 | Kangchen Pharmaceutical (603590.SH) announced that the company's board of directors recently received a written resignation report submitted by Chairman Wang Xijuan. In order for the board of directors to better serve the interests of all shareholders and lead the company's strategic development, Ms. Wang Xijuan applied to resign as chairman of the company while also resigning as chairman of the board's strategy committee. After her resignation, she continued to serve as the company's director. On July 20, 2023, the third meeting of the fourth board of directors of the company deliberated and passed the “Proposal on Election of the Chairman of the Company”, according to the “Company Law” and other national laws, regulations, rules and regulations
Kangchen Pharmaceutical (603590.SH): 2022 annual equity distribution of 10 yuan and 2 yuan
Glonway June 29丨Kangchen Pharmaceutical (603590.SH) announced that the company will implement the 2022 annual equity distribution with a cash dividend of 2 yuan (tax included) for every 10 shares. The share registration date is July 6.
Kangchen Pharmaceutical Co., Ltd.: it has received a total of 14.6649 million yuan in government subsidies related to revenue since November 12, 2020.
Kangchen Pharmaceutical (603590) announced that since November 12, 2020, the company and its subsidiaries have received a total of 14.6649 million yuan in government subsidies related to revenue and returned 730700 yuan in subsidies for new drug special projects.
Kangchen Pharmaceutical Co., Ltd.: shareholder Beijing Industrial Investment Fund has reduced its holdings of 236300 shares of the company, and the planned time for the reduction has been more than halfway through.
Kangchen Pharmaceutical (603590) announced that the company's shareholder, Beijing Industrial Development Investment Management Co., Ltd. (hereinafter referred to as "Beijing Industrial Investment Management Co., Ltd.") has reduced its holdings of 236300 shares, accounting for 0.15% of the company's total share capital, through centralized bidding. The planned time for the reduction has passed half way.
Analysis
Price Target
No Data
